| Name | cytochrome P450 3A4 |
|---|---|
| Synonyms | CP33; CYP3; HLP; CYP3A; CP34; CYP 3A4; CYP 3; CYP3A3… |
| Name | cycloheximide |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19414624 | Fan J, Liu S, Du Y, Morrison J, Shipman R, Pang KS: Up-regulation of transporters and enzymes by the receptor ligands, 1alpha,25- and analogs, in the Caco-2 cell monolayer. J Pharmacol Exp Ther. 2009 Aug;330(2):389-402. Epub 2009 May 4. The mRNA and protein expressions of the apical sodium-dependent bile acid transporter, oligopeptide transporter 1, multidrug resistance-associated protein (MRP) 3, and sulfotransferase 1E1 remained unchanged with 1,25 (OH)(2) D (3) treatment, whereas those for CYP3A4, multidrug resistance protein 1, and MRP2 were significantly increased (P < 0.05). 1,25 (OH)(2) D (3) treatment significantly enhanced MRP4 protein expression by increasing protein stability without affecting mRNA expression, as confirmed in cycloheximide experiments. |
33(0,1,1,3) | Details |
| 18334598 | Zangar RC, Bollinger N, Verma S, Karin NJ, Lu Y: The nuclear factor-kappa B pathway regulates cytochrome P450 3A4 protein stability. Mol Pharmacol. 2008 Jun;73(6):1652-8. Epub 2008 Mar 11. When the HepG2 cells were treated with cycloheximide, a general inhibitor of protein synthesis, the loss of CYP3A4 protein was accelerated by cotreatment with either proteasome or NF-kappaB inhibitors. |
88(1,1,1,8) | Details |
| 15955870 | Busi F, Cresteil T: CYP3A5 mRNA degradation by nonsense-mediated mRNA decay. Mol Pharmacol. 2005 Sep;68(3):808-15. Epub 2005 Jun 13. The extent of CYP3A5 induction was investigated after exposure to barbiturates or steroids: CYP3A4 was markedly induced in a pediatric population compared with untreated neonates. Cycloheximide prevents the recognition of PTCs by ribosomes: in transfected MCF7 and HepG2 cells, cycloheximide slowed down the degradation of exon 3B-containing splice variants, suggesting the participation of nonsense-mediated decay (NMD). |
1(0,0,0,1) | Details |